NCT07163611 - Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions

Membranous Nephropathy - PLA2R Induced

Interventions

DRUG

Obinutuzumab administration

All participants will receive obinutuzumab 1000 mg on day 1 and 15, with two additional infusions after 6 months if the anti-PLA2R antibody IFT assay is still positive with proteinuria \> 2 gram/24 hours and stable kidney function.

Trial Locations (1)

Unknown

Department of Nephrology, Radboud University Medical Center, Nijmegen

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Radboud University Medical Center

OTHER